AstraZeneca’s Lynparza-Imfinzi combo reported positive data in Ovarian Cancer

Gossamer Bio discontinued its BTK inhibitor developement in CNS Lymphoma

FDA approved Keytruda and Padcev (enfortumab vedotin-ejfv) combination for the trearment of Urothelial cancer

BioNTech and DualityBio join hands to develop two ADCs for Solid tumors